Table 2.
p-values | |||||
---|---|---|---|---|---|
Treatment | KRAS (+) (n=241) | EGFR (+) (n=275) | KRAS/EGFR wild-type (WT) (n=520) | EGFR(+)vs. EGFR | KRAS (+)WT vs. KRAS WT |
Platinum | |||||
Yes | 152 (63%) | 132 (48%) | 327 (63%) | 0.13 | |
unknown | 25 (10%) | 29 (11%) | 57 (11%) | ||
| |||||
Bevacizumab | |||||
Yes | 88 (37%) | 65 (23%) | 190 (37%) | 0.26 | |
Unknown | 27 (11%) | 39 (14%) | 64 (12%) | ||
| |||||
EGFR-TKI | |||||
Yes | 44 (18%) | 233 (85%) | 148 (28%) | <0.001 | |
Unknown | 28 (12%) | 34 (12%) | 84 (16%) |